Eli Lilly and Company

Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks (2020) Schett G, Van Den Bosch F, Baraliakos X, Sandoval D, Geneus V, Bolce R, Liu-Leage S, et al. Conference contribution Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis (2020) Guermazi A, Roemer F, Kompel A, Diaz L, Crema M, Brown M, Hickman A, et al. Conference contribution Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety (2020) Markman JD, Bolash RB, Mcalindon TE, Kivitz AJ, Pombo-Suarez M, Ohtori S, Roemer F, et al. Journal article TARGET OUTCOMES IN PSA: SIMULTANEOUS ACHIEVEMENT OF ACR50-PASI100 AND BEYOND: INSIGHTS FROM SPIRIT-H2H AT WEEK 24 (2020) Smolen JS, Behrens F, Leage SL, Sapin C, De La Torre I, Meszaros G, Schett G, et al. Conference contribution A Phase 2 Study of Galunisertib (TGF-beta 1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (2019) Kelley RK, Gane E, Assenat E, Galle PR, Merle P, Hourmand IO, Cleverly A, et al. Journal article G-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma (2019) Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, Hudecek M, et al. Journal article Secretin-Activated Brown Fat Mediates Prandial Thermogenesis to Induce Satiation (2018) Li Y, Schnabl K, Gabler SM, Willershaeuser M, Reber J, Karlas A, Laurila S, et al. Journal article Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study (2018) Van Der Heijde D, Durez P, Schett G, Naredo E, Ostergaard M, Meszaros G, De Leonardis F, et al. Journal article Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer (2017) Guarneri V, Fasching P, Fernandez Abad M, Garcia-Saenz A, Schneeweiss A, Colleoni M, Petru E, et al. Conference contribution Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer (2017) Fasching P, Fernandez Abad M, Garcia-Saenz JA, Schneeweiss A, Guarneri V, Colleoni M, Petru E, et al. Conference contribution